Lung Cancer: Global Incidence, Prevalence and Mortality to 2015
Description: In 135 statistics-packed pages, Lung Cancer:Global Incidence, Prevalence & Mortality to 2015 (published July 2010) offers an independent view of the current and future burden of lung cancer in the pharmaceutical markets of the United States, Japan, France, Germany, Italy, Spain and the United Kingdom. Building upon base data derived primarily from national statistical sources, the projections to 2015 are modelled using Espicom\'s proprietary methodology and provide an alternative set of data for analysts to add to their consensus view and base their own market models upon.
Published Date: 07/07/2010
Category: Therapies & Markets
Research Report Decription
Lung cancer is expected to account for an estimated 12.5% of all new cancer cases in the leading economies in 2010, giving it the second highest incidence, marginally behind colorectal cancer and just ahead of breast and prostate cancers.Espicom estimates that there have been 488,400 new cases of lung cancer in major markets to date in 2010 and projects this number to increase to 536,400 by 2015, a CAGR of 2.9%. The rate of incidence per 100,000 is projected to climb from 66.4 in 2010 to reach 71.4 in 2015.There is a higher incidence of lung cancer amongst the male population. In the seven markets examined, Espicom estimates 300,000 new cases of male lung cancer in 2010, compared to 188,400 in women. With a faster growing rate amongst females the margin is expected to narrow by 2015, with male incidence rising to 314,100 and female incidence climbing to 222,300. The rate of incidence per 100,000 population is expected to climb from 83.3 to 85.3 for males over the 2010 to 2015 period, against an increase of 50.2 to 58.0 for females.
Key Questions Answered:
- What is the incidence of lung cancer in the Top 7 counTries 2007-2015?
- What is the One- & Five-Year Lung Cancer Prevalence in the Top 7 Countries, 2007-2015
- Whiat is the Lung Cancer Mortality in Top 7 Countries, 2007-2015?
- Thousands of original 5-year forecasts and statistics on incidence, prevalence and mortality
- Analysis of trends in 7 leading countries
- Comparison with Globocan 2008 and ACS data